Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03341962 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Dose-finding IMU-838 for Ulcerative Colitis
A Phase 2 study, sponsored by Immunic.
- Terminated
- Registry status
- Phase 2
- Development phase
- 263
- Enrollment target
NCT03341962 is a Phase 2 study that was terminated before completion, run by Immunic. The registered enrollment target is 263 participants.
The verdict
NCT03341962, a Phase 2 study, was terminated before completion, sponsored by Immunic.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 263 participants
- Enrollment target
Study Summary
This is a phase 2, multicenter, randomized, double-blind, placebo-controlled, dose-finding study to evaluate the efficacy and safety of IMU-838 for induction and maintenance therapy with an option for open-label treatment extension in moderate-to-severe ulcerative colitis (CALDOSE-1).
Interventions
- DRUG Placebo
- DRUG IMU-838
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 263 participants |
| Start Date | 2018-03-15 |
| Est. Completion | 2022-11-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03341962
The ClinicalTrials.gov registry entry for NCT03341962 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 263 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Immunic, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03341962 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03341962 about?
NCT03341962 is a clinical study titled "Phase 2 Dose-finding IMU-838 for Ulcerative Colitis". This is a phase 2, multicenter, randomized, double-blind, placebo-controlled, dose-finding study to evaluate the efficacy and safety of IMU-838 for induction and maintenance therapy with an option for open-label treatment extension in moderate-to-severe ulcerative colitis (CALDOSE-1).
What is the current status of trial NCT03341962?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 263 participants. The study started on 2018-03-15. Estimated completion is 2022-11-16.
What interventions are being tested in trial NCT03341962?
The interventions under investigation include: Placebo (DRUG), IMU-838 (DRUG).
Who is sponsoring clinical trial NCT03341962?
This trial is sponsored by Immunic, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.